Default company panoramic image
B5f2e41c 4998 46c4 8d99 12973ca2e8cb


CavtheRx has a novel approach to inflammatory disease modification and a capital efficient development plan that will enable early de-risking.

  • Stage Concept Only
  • Industry Biotechnology
  • Location New Haven, CT, US
  • Currency USD
  • Founded October 2014
  • Employees 2

Company Summary

CavtheRx is an inception stage biotechnology company focused on the development of a novel class of modulators of caveolin function with applicability to multiple sclerosis, uveitis, inflammatory bowel disease and traumatic brain injury. The core technology was developed in the laboratory of William Sessa (Yale University) and enables the modulation of signal transduction in vascular endothelial cells by a wide variety of cytokines.


  • Default avatar
    William Sessa
    Professor, Yale University
    Default avatar
    James Rosenbaum
    Chief Of Ophthalmology And Chenowith Chair, Devers Eye Institute
    Default avatar
    Gareth John
    Associate Professor, Mt Sinai School of Medicine